Top of this page
Skip navigation, go straight to the content
Categories
UCB Stories
-
UCB HY2021 financial results: Solid performance despite the pandemic – delivering on our strategy & guidance
Posted by 29-Jul-2021
-
UCB 2020 Financial Results: Continued growth while looking to the future
Posted by 25-Feb-2021
-
Resilient product portfolio drives continued company growth
Posted by 27-Jul-2020
-
UCB 2019 Financial Results: Strong growth while preparing for the future
Posted by 20-Feb-2020
-
Walking the talk: thanks to UCB's strong financial performance, we are investing in future growth
Posted by 25-Jul-2019
-
2018 marks the fifth consecutive year of profitable growth
Posted by 28-Feb-2019
-
UCB’s performance in line with expectations for 2018
Posted by 30-Oct-2018
-
Half-time analysis: UCB outlook for 2018 confirmed
Posted by 25-Jul-2018
-
Three months interim report: what are the highlights?
Posted by 25-Apr-2018
-
Laying a foundation for future growth
Posted by 22-Feb-2018
Tag cloud
- Financials
- financial results
- 2021 half-year financials
- financials
- half-year results
- interim report
- Financial results
- investors
- HY results
- investor relations
- Investor Relations
- Investor relations
- Investors
- pipeline
- UCB
- biopharma
- Crohn’s
- Parkinson’s
- first quarter
- Annual Report
- Communication
- CSR
- annual report
- Q1 2011
- revenue
- Roch Doliveux
- Annual report
- 2010
- patient-centric
- patients